According to HEDIS reports from the National Center for Quality Assurance (NCQA), less than half of people with diabetes in the United States receive the annual diabetic retinopathy exam recommended by the American Academy of Ophthalmology and American Diabetes Association. Furthermore, the compliance rate drops dramatically in subsequent years. As a result, retinopathy leads to 40,000 cases of preventable blindness and 160,000 cases of moderate vision loss each year according to the Centers for Disease Control and Prevention. Having more people tested is critical to detecting the disease early.

"Inoveon is on the leading edge of detecting vision-threatening disease from diabetes," said Stephen Fransen, M.D., Inoveon's Chief Clinical Officer. "Regular dilated retinal evaluation is a critical part of good preventive diabetes care." The National Eye Institute (NEI) and American Diabetes Association (ADA) encourage people with diabetes to get an annual dilated eye exam.

Inoveon's iScan technology delivers the National Institutes of Health gold standard quality testing using high-resolution, seven-field, color digital retinal scans to detect, stage and monitor diabetic retinopathy. Inoveon has the most clinical experience in the country, having now performed more than 65,000 cases.